# Arrowhead Pharmaceuticals Reaffirms 2026 FDA Filing Timeline for Plozasiran

- URL: https://stocks.freetheai.org/news/arrowhead-pharmaceuticals-reaffirms-2026-fda-filing-timeline-for-plozasiran-b48d14
- Published: 2026-10-12T11:00:00Z
- Category: company_news; sentiment: bullish; impact: medium
- Symbols: [NASDAQ:ARWR](https://stocks.freetheai.org/symbols/NASDAQ-ARWR)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced that its regulatory plans for plozasiran remain on schedule. The biotechnology firm expects to submit a supplemental New Drug Application for severe hypertriglyceridemia to the U.S. Food and Drug Administration by the end of 2026, followed by additional global regulatory submissions.

The upcoming submission represents a key regulatory milestone for the company's severe hypertriglyceridemia treatment. Alongside the timeline update, the firm confirmed plans to release interim trial results for ARO-MAPT, a candidate in its central nervous system pipeline. Shares of the company rose 3.31% to $62.75 following the update.

Investors will monitor the upcoming release of the interim ARO-MAPT study results and the same-day corporate webinar detailing central nervous system pipeline developments. Market participants will also track advancement toward the late-2026 FDA filing and subsequent international regulatory expansion.

## Key points

- Arrowhead Pharmaceuticals expects to submit a plozasiran sNDA for severe hypertriglyceridemia to the FDA by year-end 2026.
- The company plans to follow its FDA submission with additional international regulatory filings.
- Interim clinical trial results for ARO-MAPT will be released alongside a webinar on the CNS pipeline.
- Arrowhead Pharmaceuticals shares gained 3.31% to reach $62.75.

## Questions and answers

### When will Arrowhead Pharmaceuticals submit its FDA filing for plozasiran?

Arrowhead Pharmaceuticals expects to file a supplemental New Drug Application for plozasiran to treat severe hypertriglyceridemia with the FDA by the end of 2026, followed by international filings.

### What upcoming data readout has Arrowhead Pharmaceuticals announced?

Arrowhead Pharmaceuticals will release interim clinical trial results for ARO-MAPT and hold a same-day webinar to present updates on its central nervous system pipeline.